Adriamycin
Female Reproductive Organ Cancer
Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02272790CT.gov Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT01715168CT.gov A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer | — | Unknown | — | — | — |
NCT01375699CT.gov Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers | — | Completed | — | — | — |
NCT00182767CT.gov Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Female Reproductive Organ Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | AstraZeneca | P2 | BB · 71 |
| Carboplatin | AbbVie | P2/3 | BB |
| Indocyanine Green | Istanbul University | P4 | BB |
| Atezolizumab | M.D. Anderson Cancer Center | P2 | B |
| Nivolumab | Clovis Oncology, Inc. | P2 | B |
| Ipilimumab | M.D. Anderson Cancer Center | P2 | B |
| Normal Human Serum Albumin | Joachim Zdolsek | P4 | B |
| Ringer'S Acetate | Joachim Zdolsek | P4 | B |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | B |
+42 more in the Female Reproductive Organ Cancer cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Adriamycin in Female Reproductive Organ Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/adriamycin-female-reproductive-organ-cancer-87492
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →